cetuximab

ClinicalAugust 18, 2026

Merck initiates trial for calderasib in KRAS G12C mCRC with mFOLFOX6

Merck Sharp & Dohme LLC has initiated a clinical trial (NCT06997497) to evaluate the safety and efficacy of calderasib in combination with cetuximab and mFOLFOX6 for patients with unresectable locally advanced or metastatic colorectal cancer harboring the KRAS G12C mutation.

ClinicalJuly 9, 2026

Phase II/III Trial Evaluates Docetaxel-Cetuximab with Atezolizumab in High-Risk Head and Neck Cancer

A phase II/III trial is assessing the efficacy of combining radiation therapy with docetaxel, cetuximab, and atezolizumab in high-risk head and neck cancer patients.

Competitive

Sponsor company

Recent signals(3)

Merck initiates trial for calderasib in KRAS G12C mCRC with mFOLFOX6

Phase II/III Trial Evaluates Docetaxel-Cetuximab with Atezolizumab in High-Risk Head and Neck Cancer

Novel bispecific T-cell engagers show promise against EGFR resistance in cancer

Upcoming milestones

Related catalysts(2)

Roche — cetuximab

— cetuximab

Indications

Therapeutic areas

Get signals before the market moves